Arcutis Biotherapeutics, Inc. (ARQT) Tops Q4 EPS by 24c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q4 EPS of ($1.18), $0.24 better than the analyst estimate of ($1.42). Revenue for the quarter came in at $2.96 million versus the consensus estimate of $2.02 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
• American Eagle Outfitters names new CFO, reaffirms 2026 guidance